DelveInsight’s “Chronic Rhinosinusitis Without Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology as well as the CRSsNP market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Chronic Rhinosinusitis Without Nasal Polyps Market with DelveInsight's In-Depth Report @ Chronic Rhinosinusitis Without Nasal Polyps Market Size
Key Takeaways from the Chronic Rhinosinusitis without Nasal Polyps Market Report
- In November 2024:- Insmed Incorporated- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study. The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
- In the assessment done by DelveInsight, the estimated diagnosed prevalent cases of CRSsNP in the 7MM were nearly 17,323 thousand in 2023.
- DelveInsight's estimates suggests that the number of diagnosed prevalent cases of chronic rhinosinusitis (CRS) in the US reached approximately 11,047 thousand in 2023, accounting for 52% of overall cases in the 7MM.
- The highest prevalent cases of CRS were accounted by the US in 2023 (~31,563 thousand), which are expected to show a rise in the future.
- Among the European countries, Germany had the highest diagnosed prevalent cases of CRSsNP with ~ 2,246 thousand cases, followed by the UK, which had diagnosed prevalent population of ~ 1,410 thousand in 2023. On the other hand, Spain had the lowest diagnosed prevalent population (~983 thousand cases).
- Based on gender-specific segmentation, females are affected the most by CRSsNP in the US, accounting for approximately 5,637 thousand cases in 2023 as compared to ~3,311 thousands in males.
- The leading Chronic Rhinosinusitis without Nasal Polyps Companies such as Sanofi, Lyra Therapeutics, Insmed, Inc., Regeneron Pharmaceuticals, and others
- Promising Chronic Rhinosinusitis without Nasal Polyps Pipeline Therapies such as LYR-210, LYR-220, Brensocatib, DUPIXENT, and others
Stay ahead in the Chronic Rhinosinusitis Without Nasal Polyps Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Rhinosinusitis Without Nasal Polyps Market Outlook
Chronic Rhinosinusitis without Nasal Polyps Epidemiology Segmentation in the 7MM
- Total Prevalent Cases
- Total Diagnosed Prevalent Cases
- Total Diagnosed Prevalent Cases
- Gender-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Chronic Rhinosinusitis Without Nasal Polyps epidemiology trends @ Chronic Rhinosinusitis Without Nasal Polyps Prevalence
Chronic Rhinosinusitis Without Nasal Polyps Marketed Drugs
- XHANCE (fluticasone propionate): Optinose US Inc.
Optinose US Inc.’s first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 μg, is therapeutic, utilizing a proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and if approved, chronic rhinosinusitis without nasal polyps. In September 2017, the US FDA approved XHANCE for treating nasal polyps in patients aged 18 or older, and it was made widely available through commercial channels in April 2018. In March 2024, the FDA broadened the indications for fluticasone propionate (XHANCE) nasal spray to include treatment for chronic rhinosinusitis in adults without nasal polyps. Notably, about two-thirds of individuals with chronic rhinosinusitis, or chronic sinusitis, are without nasal polyps. This milestone marked XHANCE as the first and only treatment option available for CRSsNP.
Chronic Rhinosinusitis Without Nasal Polyps Emerging Drugs
- LYR-210: Lyra Therapeutics
LYR-210 is an implantable anti-inflammatory drug matrix designed to deliver mometasone furoate (MF) locally and consistently to inflamed mucosal tissue for up to 6 months in surgically naïve patients with chronic rhinosinusitis (CRS), both with and without nasal polyps, who have not responded to previous medical treatments. The implant facilitates sustained drug release at challenging nasal inflammation sites without requiring patient compliance, while minimizing systemic side effects typical of oral steroids. Administered via a brief, noninvasive office procedure by an ENT specialist using a single-use applicator under endoscopic guidance, LYR-210 is currently undergoing a Phase III program named ENLIGHTEN, which includes two pivotal trials. These trials, ongoing in the US and Europe, are essential for assessing the drug’s efficacy and safety and will support the FDA submission. Enrollment in ENLIGHTEN 2, the second pivotal Phase III trial of LYR-210 in CRS, is ongoing; enrollment completion is expected in the second half of 2024. Topline results from ENLIGHTEN 2 are expected in the first half of 2025. Results from the ENLIGHTEN 1 52-week extension study are expected in Q4 2024.
- LYR-220: Lyra Therapeutics
LYR-220 is aimed at chronic rhinosinusitis (CRS) patients who still need treatment to control symptoms despite having undergone sinus surgery. Like LYR-210, LYR-220 uses mometasone furoate (MF) but features a larger matrix suited for patients with an enlarged nasal cavity post-surgery. In September 2023, positive topline results from the BEACON trial were reported. The drug achieved statistically significant improvements in key symptoms (nasal obstruction, nasal discharge, facial pain/pressure) as early as week 4, with sustained benefits through week 24. Significant enhancements were also seen in SNOT-22 scores and sinus opacification on CT scans. Additionally, LYR-220 showed notable improvement in loss of smell in a subset of patients. The trial met its primary safety endpoint, with no serious adverse events reported. Commonly reported adverse events included sinusitis, nasopharyngitis, bronchitis, and COVID-19.
Get In-Depth Knowledge on Chronic Rhinosinusitis Without Nasal Polyps Market Trends and Forecasts with DelveInsight @ Chronic Rhinosinusitis Without Nasal Polyps Treatment Market
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Outlook
Chronic Rhinosinusitis Without Nasal Polyps has a diverse treatment classification associated with the disease landscape. The primary goal of treatment for chronic rhinosinusitis without nasal polyps is to reduce inflammation, control symptoms, and improve the patient’s quality of life. Antibiotics and corticosteroids are major revenue generators in the current treatment landscape. The use of antibiotics and corticosteroids (intranasal and oral) is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage CRSsNP. Chronic rhinosinusitis with sinusitis without nasal polyps (CRSsNP) presents a distinct therapeutic challenge due to its prevalence in patients who do not benefit from conventional treatments. Management typically involves a combination of nasal corticosteroids, saline irrigation, and sometimes systemic medications to address inflammation and manage symptoms. The introduction of targeted treatments, such as fluticasone propionate (XHANCE) nasal spray, has marked a significant advancement in the field. XHANCE, recently approved by the FDA for CRSsNP, provides localized, sustained delivery of corticosteroids via an exhalation delivery system, specifically designed for patients without nasal polyps.
Scope of the Chronic Rhinosinusitis without Nasal Polyps Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Chronic Rhinosinusitis without Nasal Polyps Companies: Sanofi, Lyra Therapeutics, Insmed, Inc., Regeneron Pharmaceuticals, and others
- Chronic Rhinosinusitis without Nasal Polyps Pipeline Therapies: LYR-210, LYR-220, Brensocatib, DUPIXENT, and others
- Chronic Rhinosinusitis without Nasal Polyps Market Dynamics: Attribute Analysis of Emerging Chronic Rhinosinusitis without Nasal Polyps Drugs
- Chronic Rhinosinusitis Without Nasal Polyps Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Chronic Rhinosinusitis Without Nasal Polyps Unmet Needs, KOL’s views, Analyst’s views, Chronic Rhinosinusitis without Nasal Polyps Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Rhinosinusitis Without Nasal Polyps Market Report @ Chronic Rhinosinusitis Without Nasal Polyps Market Drivers and Barriers
Table of Content
1. Key Insights
2. Report Introduction
3. Country-wise Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Overview at a Glance
4. Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Overview by Therapies
5. Methodology of Chronic Rhinosinusitis Without Nasal Polyps Epidemiology and Market
6. Executive Summary of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
7. Key Events
8. Disease Background and Overview: CRSsNP
9. Epidemiology and Patient Population
10. Patient Journey
11. Emerging Drugs
12. CRSsNP: Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
